Tudor Investment Corp ET AL Sells 80,909 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Tudor Investment Corp ET AL cut its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 45.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 98,175 shares of the biotechnology company’s stock after selling 80,909 shares during the quarter. Tudor Investment Corp ET AL’s holdings in BioCryst Pharmaceuticals were worth $745,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of BCRX. Focus Partners Wealth purchased a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at $77,000. Farther Finance Advisors LLC increased its stake in BioCryst Pharmaceuticals by 326.8% in the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 8,109 shares during the last quarter. Vestmark Advisory Solutions Inc. purchased a new stake in BioCryst Pharmaceuticals during the third quarter valued at about $81,000. Mercer Global Advisors Inc. ADV purchased a new stake in BioCryst Pharmaceuticals during the third quarter valued at about $81,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in BioCryst Pharmaceuticals during the third quarter worth about $81,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Insider Activity at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 150,000 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the transaction, the insider directly owned 400,703 shares of the company’s stock, valued at $3,666,432.45. The trade was a 27.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on BCRX shares. Evercore started coverage on BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective on the stock. Weiss Ratings upgraded BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Wednesday, March 4th. HC Wainwright upped their target price on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Royal Bank Of Canada reduced their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.64.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $9.52 on Wednesday. The business has a 50-day moving average of $7.88 and a 200 day moving average of $7.50. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.31. The stock has a market capitalization of $2.39 billion, a PE ratio of 7.93 and a beta of 0.74.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $1.05. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The business had revenue of $163.28 million for the quarter, compared to analysts’ expectations of $151.32 million. During the same period in the previous year, the firm earned ($0.13) EPS. The business’s quarterly revenue was up 209.1% on a year-over-year basis. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.